Gator Psychiatry

Post by JAMA on X opiate care

JAMA

A recent MMWR report applied data from the 2022 National Survey on Drug Use and Health to estimate the opioid cascade of care.

Viewpoint by ⁦‪@NIAIDNews‬⁩ Arwady, Delphin-Rittmon, and Volkow provide the implications for clinical practice.

ja.ma/4e6iJDu pic.twitter.com/qRMurpbvyh

9/4/24, 7:00 AM

Joseph Thornton

Post by Adam Grant on X. 6 biotypes depression

Adam Grant

⁦‪@AdamMGrant‬⁩

Depression and anxiety aren’t single conditions. New research identifies 6 different biotypes that vary in brain circuit activation, symptoms, and reactions.

Some respond better to therapy; others to medication.

Mental health isn’t one-size-fits-all. Neither are treatments. pic.twitter.com/qDaOPVHU6f

9/3/24, 12:45 PM

Joseph Thornton

Post by CAPES Suicide Prevention on X. JASPR

CAPES Suicide Prevention

⁦‪@CAPESuicidePrev‬⁩

Dr. Dave Jobes with ⁦‪@CAMScare_tweets‬⁩ mentioned Jaspr Health in this discussion today. Jaspr makes use of time where patients would be waiting for care in the ED. Jaspr provides support with making a safety plan and a host of coping skills videos and shared stories.

8/28/24, 3:28 PM

Joseph Thornton

Post by EASO on X Infograph obesity facts

EASO

⁦‪@EASOobesity‬⁩

Obesity: The Hard Facts

23% of adults were estimated to have obesity in the EU in 2016.

Obesity is the No.1 independent cause of premature mortality.

10-13% of deaths in parts of Europe are linked to obesity.

Treat obesity the same way as other NCDs.
easo.org/policy/ pic.twitter.com/zwBH4V1WuK

8/28/24, 2:32 AM

Joseph Thornton

Post by JAMA Psychiatry on X. Boaters psychosis in dementia

JAMA Psychiatry

⁦‪@JAMAPsych‬⁩

Plasma levels of p-tau181 and NfL may be used as a biomarker for psychosis in mild cognitive impairment and Alzheimer disease, with potential implications for disease monitoring and treatment strategies. ja.ma/46A3Oz1

8/27/24, 6:00 AM

Joseph Thornton

Post by Norman Fixel Institute for Neurological Diseases on X

Norman Fixel Institute for Neurological Diseases

⁦‪@FixelInstitute‬⁩

New research from Fixel and UF Health reveals a promising link between GLP-1 receptor agonists and a reduced risk of Parkinson’s in older adults with type 2 diabetes. The study found a 23% lower risk of PD among GLP-1RA users compared to DPP4i users.
🔗: …mentdisorders.onlinelibrary.wiley.com/doi/10.1002/md… pic.twitter.com/ymXGUgCv5v

8/27/24, 3:30 PM

Joseph Thornton

Post by Michael Okun on X. GLP 1 prevent Parkinson’s

Michael Okun

⁦‪@MichaelOkun‬⁩

Do glucagon-like peptide-1 receptor agonists (GLP-1’s) reduce the risk of later Parkinson’s disease in type 2 diabetes? Tang and colleagues ⁦‪@FixelInstitute‬⁩ ⁦‪@UFPharmacy‬⁩ take apart this question in a new paper published in the ⁦‪@MDJ_Journal‬⁩. Do you know where the term ‘let the cat… pic.twitter.com/sznpogiqIX

8/27/24, 8:50 AM

Joseph Thornton

Post by deprescribing.org. Evidenced based tools for individualized care

deprescribing.org

⁦‪@deprescribing‬⁩

⁦‪@AmyTPage‬⁩ ⁦‪@KennyPharmPhD‬⁩ ⁦‪@drhurwitz87‬⁩ ⁦‪@DeprescribeAU‬⁩ Check out our evidence-based tools that can guide patient-specific #Deprescribing interventions!
buff.ly/48I6Ph9

8/24/24, 12:00 PM

Joseph Thornton

Semaglutide in Psychiatry—Opportunities and Challenges | Diabetes | JAMA Psychiatry | JAMA Network

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2822341

Joseph Thornton

Post by JAMA on infographic obesity rx

JAMA

⁦‪@JAMA_current‬⁩

Obesity is associated with multiple comorbidities. This review examines the safety and efficacy of antiobesity medications in conjunction with lifestyle modification according to their mechanism of action. ja.ma/3MgehWZ pic.twitter.com/xPYwYE7clS

8/24/24, 8:00 AM

Joseph Thornton